PreCombTherapeutics AG is a privately held Swiss biotechcompany focused on in vitro cancer diagnostic to improve cancer management. It’s automated microtumor-based 3DTwin™ technology enables clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcome.
Looking for a particular PreComb employee's phone or email?
The PreComb annual revenue was $5.8 million in 2026.
Olivier Mauti is the Chief Technology Officer and Co-Founder of PreComb.
4 people are employed at PreComb.
PreComb is based in Hombrechtikon, Zurich.
The NAICS codes for PreComb are [5417, 54, 541, 54171, 541711].
The SIC codes for PreComb are [87, 873].